-
公开(公告)号：US20240150494A1
公开(公告)日：2024-05-09
申请号：US18550059
申请日：2022-03-10
Applicant: The Rockefeller University
Inventor： Stylianos Bournazos , Jeffrey V. Ravetch , Aaron Gupta , Kevin Kao
IPC: C07K16/42 , A61K38/47 , A61K38/48 , A61K39/395 , A61K45/06 , A61K47/68 , A61P31/14 , C12N9/24 , C12N9/52 , G01N33/569
CPC classification number: C07K16/4216 , A61K38/47 , A61K38/4873 , A61K39/39566 , A61K45/06 , A61K47/6873 , A61P31/14 , C12N9/2402 , C12N9/52 , C12Y302/01096 , C12Y304/2201 , G01N33/56983 , C07K2317/24 , C07K2317/40 , C07K2317/569 , C07K2317/76 , C07K2319/30 , G01N2333/165 , G01N2333/185 , G01N2440/38 , G01N2469/20
Abstract: This disclosure is based, at least in part, on an unexpected discovery that the novel nanobodies and variants thereof are able to specifically bind afucosylated or sialylated IgG Fc glycoforms. Glycosylation of the IgG Fc domain is a major determinant of the strength and specificity of antibody effector functions, modulating the binding interactions of the Fc with the diverse family of Fcγ receptors. These Fc glycan modifications, such as removal of the core fucose residue, are newfound clinical markers for predicting severity of diseases, such as diseases caused by dengue virus (DENV) or SARS-CoV-2. However, it remains challenging to accurately distinguish specific IgG glycoforms without costly and time-intensive methods. The novel glycol-specific nanobodies and variants thereof, as disclosed herein, can be used as rapid clinical diagnostics or prognostics to risk stratify patients with viral and inflammatory diseases.
-
公开(公告)号：US20230181701A1
公开(公告)日：2023-06-15
申请号：US17926223
申请日：2021-05-18
Applicant: Hansa Biopharma AB
Inventor： Christian Kjellman
CPC classification number: A61K38/4873 , C12Y304/2201 , A61K38/47 , C12Y302/01169 , A61K35/17 , A61P37/06 , A61P7/04
Abstract: The present invention relates to methods for enhancing adoptive cell transfer immunotherapy by administering a protein that has IgG cysteine protease or IgG endoglycosidase activity.
-
公开(公告)号：US20240271115A1
公开(公告)日：2024-08-15
申请号：US18570529
申请日：2022-06-14
Inventor： Haiyan Fu , Tierra Bobo , Preston Samowitz , Brian Kuhlman , David Forrest Thieker
CPC classification number: C12N9/52 , A61K38/4873 , A61K48/0083 , C12Y304/2201 , A61K38/00
Abstract: This invention relates to methods and compositions for inhibiting or depleting antibodies, e.g., total IgG including neutralizing antibodies. In particular, the invention relates to methods of inhibiting or depleting antibodies against a heterologous agent when the heterologous agent is administered to a subject, comprising administering to the subject an effective amount of recombinant or modified Streptococcus pyogenes IgG degrading enzyme (IdeS) prepared from codon-optimized nucleic acids and/or modified nucleic acids, thereby inhibiting or depleting antibodies and inhibiting neutralization of the heterologous agent, e.g., to improve viral vector-mediated gene therapy.
-
公开(公告)号：US20100303781A1
公开(公告)日：2010-12-02
申请号：US11921770
申请日：2006-06-08
Applicant: Lars Björck , Rikard Holmdahl , Kutty Selva Nandakumar
Inventor： Lars Björck , Rikard Holmdahl , Kutty Selva Nandakumar
CPC classification number: A61K38/4873 , C12Y304/2201 , Y10S424/80 , Y10S424/81
Abstract: The invention provides use of an IdeS polypeptide, or a polynucleotide encoding an IdeS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.
Abstract translation: 本发明提供了IdeS多肽或编码IdeS多肽的多核苷酸在制备用于治疗或预防由IgG抗体介导的疾病或病症的药物中的用途。
-
Patent Agency Ranking
公开(公告)号：US20160231329A1
公开(公告)日：2016-08-11
申请号：US15023042
申请日：2014-09-18
Applicant: GENOVIS AB
Inventor： Fredrik OLSSON , Maria NORDGREN , Malin MEJARE , Sarah FREDRIKSSON
CPC classification number: G01N33/6857 , C07K16/00 , C07K2317/53 , C12N9/6472 , C12Y304/2201 , G01N33/6854 , G01N2333/96413
Abstract: The inventions provides methods for analysing a sample of immunoglobulins, related peptides, and kits for carrying out such methods.
Abstract translation: 本发明提供了用于分析免疫球蛋白样品，相关肽和用于进行这些方法的试剂盒的方法。
-
6.发明授权Method of treating or preventing a disease or condition mediated by pathogenic IgG antibodies 有权治疗或预防致病性IgG抗体介导的疾病或病症的方法公开(公告)号：US08133483B2
公开(公告)日：2012-03-13
申请号：US11921770
申请日：2006-06-08
Applicant: Lars Björck , Rikard Holmdahl , Kutty Selva Nandakumar
Inventor： Lars Björck , Rikard Holmdahl , Kutty Selva Nandakumar
CPC classification number: A61K38/4873 , C12Y304/2201 , Y10S424/80 , Y10S424/81
Abstract: The invention provides use of an IdeS polypeptide, or a polynucleotide encoding an IdeS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.
Abstract translation: 本发明提供了IdeS多肽或编码IdeS多肽的多核苷酸在制备用于治疗或预防由IgG抗体介导的疾病或病症的药物中的用途。
-
公开(公告)号：US20230302100A1
公开(公告)日：2023-09-28
申请号：US18053676
申请日：2022-11-08
Applicant: Hansa Biopharma AB
Inventor： Christian Kjellman , Sofia Jarnum , Emma Nordahl
CPC classification number: A61K38/48 , C12N9/24 , C12N9/6472 , C12N9/6475 , C12Y304/2201 , A61K38/00 , Y02A50/30
Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
-
公开(公告)号：US20230210962A1
公开(公告)日：2023-07-06
申请号：US17909040
申请日：2021-03-03
Applicant: Hansa Biopharma AB
Inventor： Robert Bockermann , Anna-Karin Louise Robertson , Jiaxin LIN , Colin Charles ANDERSON
IPC: A61K38/48 , A61K38/47 , A61K35/17 , A61K39/395 , A61K31/69 , A61K31/675 , A61K35/28 , A61P37/06
CPC classification number: A61K38/4873 , A61K31/69 , A61K31/675 , A61K35/17 , A61K35/28 , A61K38/47 , A61K39/3955 , A61P37/06 , C12Y302/01096 , C12Y304/2201 , A61K2039/507
Abstract: The present invention relates to a conditioning regimen for the transplant of a cell, tissue or organ, optionally hematopoietic stem / progenitor cells, to a subject. The invention also relates to methods for the induction of hematopoietic chimerism in a subject. The invention also relates to methods for the prevention or treatment of a disease or condition in a subject, in which hematopoietic chimerism is induced in order to improve the benefit to the subject of a subsequent therapy. The subsequent therapy may be a cell, tissue or organ transplant or may a gene therapy administered using genetically modified hematopoietic stem cells/progenitor cells.
-
公开(公告)号：US20230142731A1
公开(公告)日：2023-05-11
申请号：US17862622
申请日：2022-07-12
Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , GENETHON , SORBONNE UNIVERSITÉ , UNIVERSITÉ DE PARIS , SPARK THERAPEUTICS, INC.
Inventor： Sébastien LACROIX-DESMAZES , Federico MINGOZZI , Jordan DIMITROV , Christian LEBORGNE , Sean ARMOUR
IPC: A61K48/00 , C12N9/24 , C12N15/113 , C12N15/86 , A61K38/48 , C12N9/64 , C12N15/861
CPC classification number: A61K48/005 , C12N9/2402 , C12N15/113 , C12N15/86 , A61K38/4873 , C12N9/6475 , C12N15/861 , C12N2310/11 , C12N2310/141 , C12N2750/14143 , C12Y302/01 , C12Y304/22 , C12Y304/2201 , G01N33/6854
Abstract: Disclosed herein are methods for treating patients that may develop or already have pre-existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.029 seconds)
